|Dr. Steven A. Cutler||CEO & Director||2.21M||N/A||1960|
|Mr. Brendan Brennan||Chief Financial Officer||914k||N/A||1979|
|Mr. Diarmaid Cunningham||Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec.||N/A||N/A||1975|
|Jonathan Curtain||VP of Corp. Fin. & Investor Relations||N/A||N/A||N/A|
|Mr. Thomas N. O'Leary||Chief Information Officer||N/A||N/A||N/A|
|Mr. Simon Holmes||Exec. VP of Investor Relations & Corp. Devel.||N/A||N/A||1967|
|Ms. Niamh Murphy||Director of Corp. Communications||N/A||N/A||N/A|
|Mr. David Green||VP of Marketing||N/A||N/A||N/A|
|Mr. Joe Cronin||Chief HR Officer||N/A||N/A||N/A|
|Ms. Dana Lynn Poff Snr.||Exec. VP of Program Management||N/A||N/A||N/A|
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICON Public Limited Company’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.